The analysts wrote, “Alimera has amended its agreement with pSivida to expand Iluvien’s indication in.””
Alimera Sciences Inc (NASDAQ:ALIM)‘s stock had its “buy” rating restated by analysts at Cowen and Company in a note issued to investors on Tuesday, July 11th. They presently have a $3.00 target price on the biopharmaceutical company’s stock. Cowen and Company’s target price suggests a potential upside of 96.08% from the stock’s previous close.
Several other analysts also recently weighed in on the stock. Zacks Investment Research upgraded shares of Alimera Sciences from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a report on Monday, July 10th. HC Wainwright set a $5.00 price target on shares of Alimera Sciences and gave the company a “buy” rating in a research report on Tuesday, July 11th. Finally, Rodman & Renshaw started coverage on shares of Alimera Sciences in a research report on Thursday, April 27th. They set a “buy” rating and a $4.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $3.38.
Shares of Alimera Sciences (NASDAQ:ALIM) traded down 1.92% during midday trading on Tuesday, reaching $1.53. The company’s stock had a trading volume of 259,605 shares. The stock’s market capitalization is $99.30 million. Alimera Sciences has a 52 week low of $1.03 and a 52 week high of $1.87. The company has a 50 day moving average price of $1.43 and a 200-day moving average price of $1.39.
Alimera Sciences (NASDAQ:ALIM) last released its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.01. The business had revenue of $10.40 million during the quarter, compared to analysts’ expectations of $10.20 million. During the same period last year, the business earned ($0.17) earnings per share. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. On average, equities research analysts expect that Alimera Sciences will post ($0.21) EPS for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of ALIM. KCG Holdings Inc. raised its position in shares of Alimera Sciences by 127.0% in the first quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 43,977 shares during the period. JW Asset Management LLC raised its position in shares of Alimera Sciences by 15.6% in the second quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock worth $1,343,000 after buying an additional 130,000 shares during the period. Finally, Kennedy Capital Management Inc. purchased a new position in shares of Alimera Sciences during the first quarter worth about $467,000. Institutional investors own 43.58% of the company’s stock.
Alimera Sciences Company Profile
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.